{"id":62354,"date":"2025-12-14T22:05:52","date_gmt":"2025-12-14T21:05:52","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/"},"modified":"2025-12-14T22:05:52","modified_gmt":"2025-12-14T21:05:52","slug":"immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/","title":{"rendered":"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors"},"content":{"rendered":"
\n

\nCompany to host webcast Monday, December 15, 2025 at 8:30 a.m. ET\n<\/p>\n

BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, in patients with progressing desmoid tumors.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\nWebcast, Presentation Slides and Conference Call Information<\/b>\n<\/p>\n

\nImmunome will host a webcast and conference call\u00a0on\u00a0Monday, December\u00a015,\u00a02025, at 8:30 a.m. ET\u00a0\/ 5:30 a.m. PT\u00a0to discuss the Phase 3 RINGSIDE trial topline results. A live webcast, which will include presentation slides,\u00a0can be accessed using this\u00a0link<\/a>\u00a0or by visiting the Events and Presentations section of the Immunome website at\u00a0https:\/\/investors.immunome.com\/events<\/a>. The conference call can be accessed by\u00a0clicking on the\u00a0call link<\/a>\u00a0and completing the online registration form, which will enable the\u00a0selection\u00a0of a dial-in number or callback from the system. A live question-and-answer session will follow the prepared remarks. Participants wishing to ask a question must do so via the conference call; the webcast will be listen-only. After the live webcast, the event will remain archived on the Immunome website for\u00a090 days.\u00a0\n<\/p>\n

\nAbout Immunome, Inc.<\/b>\n<\/p>\n

\nImmunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Contact:
\n
<\/b>Max Rosett
\n
Chief Financial Officer, Immunome
\n
investors@immunome.com<\/a>\n<\/p>\n

\nMedia Contact:<\/b>
Nicole Foderaro
\n
Real Chemistry
\n
media@immunome.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62354","6":"format-standard","7":"category-industry"},"yoast_head":"\nImmunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-14T21:05:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251214414258\/en\/2670034\/22\/Immunome_Logo_TM_Email.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors\",\"datePublished\":\"2025-12-14T21:05:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/\"},\"wordCount\":345,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251214414258\\\/en\\\/2670034\\\/22\\\/Immunome_Logo_TM_Email.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/\",\"name\":\"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251214414258\\\/en\\\/2670034\\\/22\\\/Immunome_Logo_TM_Email.jpg\",\"datePublished\":\"2025-12-14T21:05:52+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251214414258\\\/en\\\/2670034\\\/22\\\/Immunome_Logo_TM_Email.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251214414258\\\/en\\\/2670034\\\/22\\\/Immunome_Logo_TM_Email.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Pharma Trend","og_description":"Company to host webcast Monday, December 15, 2025 at 8:30 a.m. ET BOTHELL, Wash.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced the company will host a conference call and webcast on Monday, December 15, 2025 at 8:30 am ET to disclose the topline results ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/","og_site_name":"Pharma Trend","article_published_time":"2025-12-14T21:05:52+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251214414258\/en\/2670034\/22\/Immunome_Logo_TM_Email.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors","datePublished":"2025-12-14T21:05:52+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/"},"wordCount":345,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251214414258\/en\/2670034\/22\/Immunome_Logo_TM_Email.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/","url":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/","name":"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251214414258\/en\/2670034\/22\/Immunome_Logo_TM_Email.jpg","datePublished":"2025-12-14T21:05:52+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251214414258\/en\/2670034\/22\/Immunome_Logo_TM_Email.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251214414258\/en\/2670034\/22\/Immunome_Logo_TM_Email.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/immunome-to-announce-topline-results-from-phase-3-ringside-trial-of-varegacestat-in-patients-with-desmoid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Immunome to Announce Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62354","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62354"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62354\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62354"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62354"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62354"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}